BioSpace News Archive

Soaak Technologies, a leading provider of innovative health technology solutions, is pleased to announce the appointment of Kevin V Cox as its new Chief Executive Officer (CEO).

Navidea Biopharmaceuticals, Inc. today announced the Company’s Board of Directors, in consultation with G2G Ventures as Executive Consultants, has unanimously rejected an unsolicited, non-binding offer from ProPhase Labs to acquire certain assets from the Company on the terms disclosed in their press release on June 29, 2023.

BioNTX and grant partners Dallas College and the DFW Hospital Council Foundation collaborated with Swiss American CDMO to launch the Biotechnology and Healthcare Industry Alliance of North Texas (BHIANT).

Bristol-based deep tech ecosystem, Science Creates, has launched an engineering biology accelerator programme to support life science start-ups and innovators in developing ground-breaking advancements in healthcare, the environment, and quality of life.

Resverlogix Corp. (TSX: RVX) (“Resverlogix” or the “Company”) announces that certain of its 27,461,157 common share purchase warrants

Dr. Brian Cornblatt, the Chief Medical Officer of BioHarvest Sciences (CSE: BHSC) (OTCQB: CNVCF) (FSE:8MV) (“BioHarvest” or “the company”), delivered a keynote address on the “HealthConf” stage at the Collision conference in Toronto on Thursday.

Genentech, a member of the Roche Group, announced new long-term data for Evrysdi® from the open-label extension of the pivotal FIREFISH study, reinforcing its sustained efficacy and safety profile in children with Type 1 spinal muscular atrophy.

Data presented at the European Academy of Neurology Congress 2023 Teva Pharmaceutical Industries Ltd. announces further positive data from the pan-European PEARL study investigating the impact of AJOVY® on the prevention of migraine in a real-world setting,1 due to be completed in 2024.

Zealand Pharma A/S announced the submission of a New Drug Application to the US Food and Drug Administration for dasiglucagon for the prevention and treatment of low blood sugar in pediatric patients 7 days of age or older with congenital hyperinsulinism.

Stryker announced that it will report financial results for second quarter of fiscal year 2023 on Thursday, August 3, 2023.